Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance. (2020)
Attributed to:
Preclinical efficacy of an antibody of the IgE class against a melanoma-associated antigen
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.ccell.2019.12.003
PubMed Identifier: 31935375
Publication URI: http://europepmc.org/abstract/MED/31935375
Type: Journal Article/Review
Volume: 37
Parent Publication: Cancer cell
Issue: 1
ISSN: 1535-6108